OPEN END TURBO BULL OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 15:40:44 2024-05-31 EDT | ||
| 13.86 EUR | +9.39% |
|
| 1 month | +59.86% | ||
| 3 months | +17.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 13.86 | +9.39% |
| 24-05-30 | 12.67 | -1.25% |
| 24-05-29 | 12.83 | -2.36% |
| 24-05-28 | 13.14 | -9.00% |
| 24-05-27 | 14.44 | +2.85% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 03:40 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC3NX4 |
| ISIN | DE000HC3NX41 |
| Date issued | 2023-01-30 |
| Strike | 305 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.16 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.69 € |
|---|---|
| Lowest since issue | 1.65 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
